|
|
Article: Aeolus Pharmaceuticals Starts 2nd Study of AEOL 10150 as a Countermeasure to Radiation Exposure in Mice
- Article from:
- Wireless News
- Article date:
- September 16, 2009
CopyrightProvided by ProQuest LLC. (Hide copyright information)
|
Wireless News
09-16-2009
Aeolus Pharmaceuticals Starts 2nd Study of AEOL 10150 as a Countermeasure to Radiation Exposure in Mice
Type: News
Aeolus Pharmaceuticals, Inc. has announced the initiation of a second study, in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs.
In a release, the Company noted:
This study, led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University, is designed to build on the recently completed study that demonstrated the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation, and determine the most effective duration of delivery for ...